Inrig Jula

CIK 00019023681 companySAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001902368

Recent Transactions

50 trades

Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2026-09-15−32,395→ 43,605 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-09-15$63.69/sh−1,600→ 100,891 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-09-15$62.02/sh−25,390→ 119,775 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-09-15$8.93/sh+32,395→ 145,165 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-09-15$65.31/sh−400→ 100,491 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-09-15$62.62/sh−17,284→ 102,491 total
Gift
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-06-22−468→ 112,770 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-05-06$43.95/sh−311→ 113,238 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-05-05$46.65/sh−2,174→ 113,549 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-05-04$22.40/sh+20,000→ 131,473 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2026-05-04−4,250→ 4,250 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2026-05-04+8,500→ 8,500 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2026-05-04−20,000→ 34,500 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-05-04+4,250→ 115,723 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-05-04$45.00/sh−20,000→ 111,473 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-04-15$42.61/sh−1,018→ 111,473 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-04-14$41.93/sh−7,215→ 112,491 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-04-13+14,000→ 119,706 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-02-04$32.85/sh−232→ 105,706 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-02-04$32.11/sh−1,547→ 105,938 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-02-03$32.12/sh−6,956→ 107,485 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2026-01-31+75,000→ 75,000 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-01-31+28,130→ 114,441 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-01-06$37.75/sh−445→ 86,311 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2026-01-05$40.18/sh−2,031→ 86,756 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2025-12-24−15,000→ 76,000 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-12-24$42.00/sh−15,000→ 88,787 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-12-24$8.93/sh+15,000→ 103,787 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-07-01$14.65/sh−815→ 88,787 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-12$23.53/sh−2,568→ 89,602 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-10+8,000→ 92,170 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2025-02-10−8,000→ 0 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-04$20.11/sh−1,066→ 84,170 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-03$20.12/sh−4,207→ 85,236 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2025-01-31+100,000→ 100,000 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-31+30,000→ 89,443 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-06$18.76/sh−440→ 59,443 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-03$19.10/sh−2,066→ 59,883 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-10$12.98/sh−684→ 61,949 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-09$11.52/sh−2,191→ 62,633 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-05+6,750→ 64,824 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-02-01$8.53/sh−2,174→ 58,074 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2024-01-31+91,000→ 91,000 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-31+25,000→ 60,248 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-04$9.17/sh−440→ 35,248 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-03$9.48/sh−2,069→ 35,688 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-01-31+20,250→ 37,757 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2023-01-31+54,500→ 54,500 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2023-01-31+6,750→ 6,750 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-01-05$20.75/sh−442→ 17,507 total

Companies

Travere Therapeutics, Inc.
EVP, Head of R&D & CMO
$TVTX

Recent Filings

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300

SAN DIEGO, CA, 92130

View on SEC.gov